The present study was established to investigate the role of bone marrow mesenchymal stem cells (MSCs) and melatonin (MT), alone or in combination with each other for improvement of beta cell functions in STZ-induced diabetic rat model. Also, to evaluate the role of melatonin in increasing the efficacy of MSCs. Fifty two male albino rats (130-150g) were divided into six groups. Control: received phosphate buffer saline PBS; Melatonin group received melatonin (10 mg/kg b.wt. day for 2 months by oral intubation); Diabetic untreated group; Diabetic group treated with melatonin; Diabetic group treated with mesenchymal stem cells (MSCs) (A single intravenous injection of 3×106 cell in PBS )and Diabetic group treated with both stem cells and melatonin. Diabetes was induced by a single i.p. injection of 45mg/kg b.wt. of streptozotocin. The results showed that treatment of diabetic rats with either MSCs alone or in combination with melatonin resulted in an increase in body weight and pancreas weight. The biochemical analysis showed significant improvement in glucose, insulin, total antioxidant and malondialdehyde level in diabetic rats treated with either MSCs alone or in combination with melatonin. On the other hand, the results of imumuno-histochemical analysis showed that MSCs and/or melatonin treatment reduced the rate of inflammation and apoptosis of the Islet cells of pancreases as well as increased the rate of pancreatic cell division. Such results were indicated by a significant improvement in the level of TNF-α, IL-10, PCNA, and caspase-3 to levels very close to the control. The microscopic examination of Langerhans islands showed that treatment with MSCs either alone or in combination with melatonin resulted in an improvement in the tissue of the pancreas and reduced number of damaged beta cells. It can be concluded that stem cell therapy has a significant role in restoring the structural and functional efficiency of beta cells in the pancreas. The results also showed that co-treatment of stem cells and melatonin was more effective than stem cell alone. Such result may be due to the role of melatonin as an antioxidant in increasing the efficiency and vitality of stem cells.
Introdution
Diabetes mellitus (DM) is a common disease worldwide and is recognized as one of the causes leading to death (Godam et al., 2015) . The number of people suffering from diabetes worldwide is increasing at an alarming rate, and it is predicated that the number of diabetic people will rise from 382 million to 592 million by 2035 ( , both type 1 and type 2 diabetes is characterized by a marked deficit in beta-cell mass causing insufficient insulin secretion regarded of the different pathogenic events; autoimmunity for 1 and insulin resistance for 2.
Additionally, Diabetes is known to be a major disorder in which oxidative stress and free radical production have been implicated through several lines of evidence (Suzuki et al., 1999 and Brownlee, 2001) . ROS have been defined as an autocatalytic mechanism that can lead to programed cell death (Jones et al., 2000).
Curative therapy for diabetes mellitus mainly implies replacement of missing insulinproducing pancreatic β-cells, with pancreas or islet-cell transplants. The limited supply of available donor islets for transplantation, however determines that researchers must explore alternative sources of graft material or otherwise restore β cell functioning (Urbán et al., 2009 and Liu et al., 2015). Hence, a therapeutic strategy aimed to regenerate insulin-producing cells and prevent the autoimmune destruction of remnant and neogenetic β-cells are highly desirable. An attractive possibility to treat diseases like diabetes could be represented by stem cell therapy. In the last years, the use of stem cells in clinical protocols is over and over increasing (Cantarelli et al., 2015) .
Functionally stem cells can be defined as having the capacity to self-renew and the ability to generate differentiated cells. More explicitly, stem cells can generate daughter cells identical to their mother (self-renewal), as well as produce progeny with more restricted potential (differentiated cells). Besides; immunomodulatory potentials of mesenchymal stem cells (MSCs) have received great interest in regenerative and transplantation medicine (Rayan et al., 2005).
MSC differentiation is finely regulated by the action of mechanical and molecular signals from the extracellular environment. Emerging evidence suggests that melatonin may be an important regulator of precursor cell commitment and differentiation. Furthermore, radical scavenging, anti-inflammatory and anti-apoptotic properties of melatonin are expected to contribute significant homeostatic effects (Wang et al., 2013). Also, recent evidence obtained from investigations carried out on bone marrow MSC, indicates that melatonin may influence diabetes and associated metabolic disturbances not only by regulating insulin secretion, but also by providing protection against reactive oxygen species (Javier et al., 2011).
Therefore, the present study aimed to evaluate the role of bone marrow mesenchymal stem cells (MSCs) and/or melatonin for improvement of pancreatic beta cells in diabetic rat model, as well as to evaluate the role of melatonin in enhancing the performance of stem cells.
Materials and Methods

1-Chemicals:
Streptozotocin and melatonin were purchased from Sigma Chemical Company (St. Louis, U.S.A).
2-Experimental animals:-
Fifty two male albino rats (60 days-old, weighing 130:150g) were obtained from the animal house of the National Research Center, Cairo, Egypt. Rats were bred and maintained in an air conditioned animal house with specific pathogen -free conditions, and were subjected to a 12:12 h daylight/darkness and allowed unlimited access to chow and water. All the ethical protocols for animal treatment were followed and supervised by the animal facilities, National Research Center. All animal experiments received approval from the animal care committee, National Research Center.
3-Induction of diabetes:-
The animal model of diabetes was induced by a single intraperitoneal injection of STZ (45 mg/kg b.wt). dissolved immediately before administration in freshly prepared 0.1 mol/L citrate buffers (pH 4.5) (Asayama et al., 1994) . These animals are provided with 5% glucose instead of water for the first 24 hours to counteract the hypoglycemia caused by insulin released from necrotic beta cells in the pancreas. One week after STZ injection, blood samples were withdrawn from lateral tail vein to measure the blood glucose concentration using blood glucose test meter (Glcocard II GT-1640). Rats having blood glucose ranging between 140-400 mg/dl were included in the experiment while the others were excluded.
4-Preparation of bone marrow BM-derived MSC:-
Bone marrow was harvested from 6-week-old male white albino rats by flushing the tibiae and femurs with Dulbecco's modified Eagle's medium (DMEM, GIBCO/BRL) and supplemented with 10% fetal bovine serum (GIBCO/BRL). Nucleated cells were isolated with a density gradient [Ficoll/Paque (Pharmacia)] and suspended in complete culture medium supplemented with 1% penicillin-streptomycin (GIBCO/BRL). Cells were incubated at 37°C in 5% humidified CO2. When large colonies developed (80-90% confluence), cultures were washed twice with phosphate buffer saline (PBS (Lonza Company, Swiss) and the cells were trypsinized with 0.25% trypsin in 1 mM EDTA (GIBCO/BRL) for 5 min at 37°C. Cells were centrifuged and suspended in serum supplemented medium and incubated in 50 cm 2 culture flask (Falcon). MSCs were identified by their adherence to the plastic surface and their power to differentiate into osteocytes and chondrocytes (Seo et al., 2009 and Johnston et al., 1998) as well as by their morphology. CD29 (+ve), CD34 (-ve), CD90 (+ve) genes expressions were detected as markers of MSCs by flow cytometry. Dead cells were detected by using trypan blue dye, while the viable cells were counted using hemocytometer. 
Flow cytometry
5-Experimental design:-
Fifty two male albino rats were divided into 6 groups as follows: -1-Control (6 rats): rats received phosphate buffer saline (150 mg/kg b.wt).
2-Melatonin (MT) (6 rats): rats received melatonin by oral gavage (10 mg/kg b.wt., daily for 2 months).
3-Diabetic (DM) (10 rats): maintained untreated (was regarded as diabetic control).
4-DM+MT (10 rats): diabetic rats treated with melatonin in the same manner and dosage as mentioned before. 6-DM+ MSCs +MT (10 rats): diabetic rats administered both stem cells and melatonin together in the same manner and dosages as mentioned before.
5-DM+MSCs
The mean body weights were recorded once a week during the experimental period.
After 2 month of MSCs administration, all rats were sacrificed under ether anthesia at fasting state, and the pancreas was weighted and fixed in formalin for histopathological and immunohistological investigation. Blood was withdrawn from the heart into tubes then serum samples were separated by centrifugation at 3000 rpm for 15 min. for biochemical examinations (serum levels of insulin, glucose, malondialdehyde (MDA), total antioxidant capacity (TAC) and interleukin 10 (IL-10)). By the end of the experimentation, the relative and absolute weights were recorded for pancreatic tissues.
Results
Characterization and identification of MSCs:
MSCs in culture were identified morphologically by their fusiform shape and their adhesiveness. Fig.1 (A-C). Also, MSCs were identified by surface markers (CD29 (+ve), CD90 (+ve) and CD34 (-ve)) and detected by flow cytometry. 
Homing of MSCs:
PKH26 labeled stem cells were detected in in the islets of Langerhans after 10 days of MSCs transplantation, strong homing of labeled cells was observed in pancreatic sections treated with mesechymal stem cells and melatonin together. 
Biochemical analysis:
In the present study there are no significant changes between the control and MT groups. On the other hand, there are statistical changes between control and diabetic model (MD group).
As compared to MD rats, the body weights and the absolute pancreatic weights recorded statistical increase in DM+MT or DM+MSCs, with best results in companied injection (DM+MT+MSCs). 
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As shown in fig. (5), the insulin level decreased (p<0.001) with a parallel increase of glucose level (p<0.001) in the diabetic rats (DM) as compared to control. After the treatment, reversed parallel results were observed as compared to DM rats as follows: the treatment with mesenchymal stem cells (DM+MSCs) or melatonin (DM+MT) caused a significant increase (p<0.05) in serum insulin levels. Notably, the companied treatment with mesenchymal stem cells and melatonin (DM+MT+MSCs) raised insulin level to a highly significant value (p<0.001). On the other hand, an important observation was that, the glucose level decreased very highly significantly in the serum of all diabetic rats after the treatment with mesenchymal stem cells, melatonin and mesenchymal stem cells and melatonin.
As compared to DM rats, the treatment with melatonin recorded a significant reduction (p<0.05) in MDA level. As more important result, the companied treatment with mesenchymal stem cells and melatonin (DM+MT+MSCs) decreased the MDA level to a highly significant value (p<0.001). However, no significant change was observed between the diabetic rats and those treated with mesenchymal stem cells. fig.(6) .
In the current study, although TAC values increased non-significantly in diabetic rats treated with either mesenchymal stem cells or melatonin in relation to the diabetic untreated ones, it recorded a highly significant increase (p<0.01) after the companied treatment with mesenchymal stem cells and melatonin together.
Moreover, low level of serum anti-inflammatory cytokine IL-10 in diabetic model showed degrees of improvement after the treatments. In more details, the treatment with melatonin induced a significant increase (p<0.05) in IL-10, while the treatment with mesenchymal stem cells recorded a highly significant increase (p<0.01). Additionally, the companied treatment with mesenchymal stem cells and melatonin raised IL-10 to a very highly significant value (p<0.001). fig.(6) . 
Immunohistochemistry:
The results showed that total cell count which expressed PCNA immune reactivity in pancreatic islets decreased significantly for diabetic rats as compared to control. In contrast, PCNA positive cells increased (p<0.001) for treated rats [(DM+MT), (DM+MSCs) or (DM+MT+MSCs)] as compared to diabetic rats (DM). Notably, the expressions of PCNA immune reactivity increased (p>0.01) in the pancreatic islets of rats treated with (mesenchymal stem cells accompanied by melatonin (DM+MT+MSCs) as compared to those treated with mesenchymal stem cells alone (DM+MSCs) (Figs.7 & 8) .
Caspase-3 and TNF-α immune reactivity which showed very highly significant increases (p<0.001) in pancreatic islets for the diabetic rats (DM) began to decrease gradually with statistical changes after the treatment, and the most observed reduction was recorded after the accompanied treatment (DM+MT+MSCs). Note the statistical decrease of caspase-3 in the accompanied treatment as compared to the treatment with stem cells alone (p<0.001) (Figs.7, 9 & 10) . 
Histopathological studies:
Diabetic Langerhans cells showed darkly stained pyknotic cells and karyolysis and the islet cells contained vacuolated cytoplasm and slight congestion. Necrotic cells were encountered in different regions. Pancreatic tissues also showed reduction in the value and number of islets of Langerhans and irregular shape. Fig. 11 (A &B). Melatonin treatment caused improvement of islet cells in different parts of tissue, while pyknotic nuclei, necrotic areas and less congestion were observed. Fig. 11 
(C).
Pancreatic sections of rats receiving a single intravenous injection of stem cells (3×106 cell) appeared with nearly regular shape and regenerated cells in numerous islets. Fig. 11(D) . Diabetic rats treated with both stem cells accompanied with melatonin for 2 month showed amelioration of some cells of islets of Langerhans that contain nearly normal nuclei while other cells were abnormal with either pyknotic or karyolitic nuclei. Slightly vacuolated space was mostly still evident. Fig. 11 (E). 
Discussion
The present study revealed a marked depression in body weight of male albino rats given streptozotocin. However, MSCs and/or melatonin exhibit improvement in body weights of rats. The improvement due to MSCs may be attributed to their ability in self-renewing and differentiation into a variety of tissues (Alai et al., 2014) . Meanwhile, the positive effect of melatonin upon body weight may be related to its possible role in ameliorating the oxidative damage induced by STZ in rats (Sekkin et al., 2015) .
In the present study the treatment with melatonin or MSCs alone or together revealed statistical increase in the blood insulin, while revealed statistical decrease in blood glucose levels ) showed that co-transplantation of electro fused MSCs and islet cell in rats improved blood glucose level due to bi-directional reprogramming of both β-cells and MSCs nuclei, thereby allowing the insulin gene expression. Moreover, it also resulted in increased islet cells proliferative capability and decreased apoptosis.
In the present work, treatment with melatonin or MSCs reduced MDA level and increased TAC level as compared to diabetic rats; the best result was in companied injection with both melatonin and MSCs together (p< 0.01). This may be attributed to that melatonin is an efficient scavenger of OH, peroxynitrite anion (ONOO¯), O2, nitric oxide radical (NO) and peroxy radicals. Moreover, it enhances the ability of cells to resist oxidative damage by inhibiting the pro-oxidant nitric oxide synthase (Reiter et al., 1998) . It considered as an important component of the antioxidant profile of many tissues and cells (Armagan et al., 2006) . On the other hand, Volarevic et al. (2016) reported that MSCs produce cytokines, chemokines, and growth factors that robustly regulate cell behavior in a paracrine fashion during the remodeling process, and their ability to act on profibrotic factors such as oxidative stress, hypoxia. Therefore, besides their ability to differentiate into many cell lines, there is secretion of a wide range of biological molecules by MSCs, such as growth factors, cytokines and chemokines.
Macrophages are key inflammatory cells mediating inflammation in experimental and human diabetes. Activated macrophages elaborate a host of proinflammatory, profibrotic, and antiangiogenic factors. These macrophage-derived products include but are not limited to TNF-α, IL-1, IL-6, reactive oxygen species (ROS) (Galkina et al., 2006) . Also TNF-α causes induction of apoptosis and necrotic cell death (Laster et al., 1988 and Boyle et al., 2003) .
Serum anti-inflammatory cytokine IL-10 in diabetic model showed degrees of improvement after the treatments. In more details, the treatment with melatonin induced a significant increase (p<0.05) in IL-10, while the treatment with MSCs recorded a highly significant increase (p<0.01). Additionally, the companied treatment with MSCs and melatonin raised IL-10 to a very highly significant value (p<0.001). in contrast, the inflammatory cytokine, TNF-α immune reactivity which showed very highly significant increases (p<0.001) in pancreatic islets for the diabetic rats began to decrease gradually with statistical changes after the treatment, and the most observed reduction was recorded after the companied treatment.
Melatonin has been shown to possess anti-inflammatory effects. Its ability to directly scavenge toxic free radicals reduces macromolecular damage in all organs that contribute to the inflammatory response and associated tissue destruction (Retier et al., 2000) .
The therapeutic potential is attributed to unique MSCs properties of specific homing to damaged tissues, inhibiting immune and inflammatory responses at the target sites, and facilitating repair of the damaged tissues. MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammation (Newman et al., 2009 ). According to Aggarwal and Pittenger (2005) , MSCs altered the cytokine secretion profile of dendritic cells (DCs), T-helper cells and NK cells to induce anti-inflammatory or tolerant phenotype, as a specific function, MSCs caused mature DC type 1 to decrease secretion of TNF alpha and mature DC type 2 to increase secretion of IL-10, additionally, MSCs caused an increase the proportion of present regulatory T cells. These properties of MSCs render these cells especially attractive for therapeutic application in several inflammatory disease, as well as in regenerative medicine (Togel et al., 2007) .
In the present study, the proliferative capacity of the islets cells of Langerhans (PCNA) increased meanwhile the apoptotic activity (caspace-3) decreased in MSC and/or Melatonin treated diabetic rats. These results are in agreement with Gobbo et al. (2015) attributed the significant increase of PCNA and decrease in caspace-3 to the ability of melatonin to attenuate the production of reactive oxygen species (ROS) and also regulating the expression of proteins of the apoptotic pathways and have been related to the anti-apoptotic property of this neurohormone, and can also corroborate the protective action of melatonin because PCNA is also involved in DNA damage repair and epigenomic maintenance. The present study revealed slight improvement in histopathological alterations in the treatment of diabetic group with melatonin. These alterations were manifested as diffused vacuolar degeneration, pyknotic nuclei in addition to moderate congestion in islets of langerhans. melatonin participation in pancreatic regeneration was attributed to its ability to scavenge free radicals as an antioxidant by stimulating messenger ribonucleic acid (mRNA) levels and activities of SOD and GPx ( Moreover, presented results showed increases in the body weight gain, insulin level, TAC, IL-10 and PCNA of diabetic rats treated with both melatonin and MSCs in relation to diabetic ones, while recorded decreases in glucose level, MDA, TNF-α and caspace-3 and detected highly improvement in histological pancreatic tissues.
More supporting result is that MSCs strongly homed in pancreatic tissues treated with MSCs and melatonin together than those treated with MSCs alone. These better results may be attributed to oxidative stress may has a negative impact on the survival of transplanted MSCs, and it has been suggested that melatonin may be an effectively protective agent against oxidative stress-induced MSCs apoptosis (Wang et al., 2013) . In conclusion, the present results indicated that melatonin may improve the mobility and therapeutic role of MSCs in diabetic rats. 
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